Cancer
  • How Does Gastric Adenocarcinoma Develop?

How Does Gastric Adenocarcinoma Develop?

Overexpression of the peroxisome proliferator-activated receptor delta (PPARD) in gastric progenitor cells results in inflammation, dysplasia, and tumor formation in mice, researchers report in the July issue of Gastroenterology. Strategies to reduce PPARD in gastric progenitor cells might lead to treatments for stomach cancer. Gastric carcinogenesis is associated with chronic inflammation. The

Read more
  • Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Chronic infection with the hepatitis C virus (HCV) causes epigenetic changes in liver cells that alter gene expression patterns and continue to affect risk for hepatocellular carcinoma (HCC), regardless of patients’ response to direct-activating antiviral (DAA) agents, researchers report in the June issue of Gastroenterology. These alterations might be targeted

Read more
  • Are There Early Signs of Pancreatic Cancer?

Are There Early Signs of Pancreatic Cancer?

Changes in blood glucose and lipid levels occur up to 18 months before a diagnosis of pancreatic cancer, researchers report in the May issue of Gastroenterology. These changes might be used in combination with other risk factors to detect pancreatic cancer at earlier stages. One reason for the high mortality

Read more
  • How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

How Does Estrogen Receptor Signaling Promote Growth of Liver Tumors?

The G-protein–coupled estrogen receptor (GPER1) is a hepatic sensor of estrogen that regulates liver growth during development, regeneration, and tumorigenesis, researchers show in a study of zebrafish and human liver published in the May issue of Gastroenterology. Inhibitors of GPER1 might be developed for liver cancer prevention or treatment. Liver cancer

Read more
  • Can Surveillance be Extended or Eliminated for Some Patients With Barrett’s Esophagus?

Can Surveillance be Extended or Eliminated for Some Patients With Barrett’s Esophagus?

Two articles in the April issue of Clinical Gastroenterology and Hepatology show that surveillance intervals might be lengthened or even discontinued for subgroups of patients with Barrett’s esophagus. Stable non-dysplastic Barrett’s esophagus (NDBE) has a low risk of progression to high-grade dysplaisa (HGD) or esophageal adenocarcinoma (EAC), Yonne Peters et al

Read more
  • REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

CRISPR-Cas9 technology can be used to engineer organoids for studies of gastrointestinal development and disease pathogenesis. In the February issue of Gastroenterology, Masayuki Fujii et al review derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 has advanced studies of the digestive system. CRISPR-Cas9 genome editing technology allows researchers to

Read more
  • REVIEW: Balancing Benefit vs Risk of Immunosuppressive Therapy for IBD

REVIEW: Balancing Benefit vs Risk of Immunosuppressive Therapy for IBD

Inflammatory bowel diseases (IBD) and their treatments, particularly immunosuppressive drugs, increase risk of infections and cancers. However, by promoting mucosal healing, these agents reduce risks of infections related to intestinal lesions, malnutrition, intravenous devices, and IBD surgeries and reduce risk of cancers associated with chronic mucosal inflammation. Laurent Beaugerie and Julien Kirchgesner

Read more
  • Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Addition of genetic information to clinical factors does not increase identification of individuals at risk for esophageal adenocarcinoma, researchers report in the January 2019 issue of Gastroenterology. New screening and risk evaluation methods are needed to improve early detection of esophageal adenocarcinoma, because most patients receive a diagnosis at a late

Read more

Is Endoscopic Submucosal Dissection the Best Treatment for Esophageal Cancer?

Lower proportions of patients with T1am2/m3 or T1b early-stage esophageal squamous cell carcinomas (EESCCs) treated with endoscopic submucosal dissection (ESD) have perioperative adverse events or disease-specific death after a median follow-up time of 21 months, researchers report in the January issue of Clinical Gastroenterology and Hepatology. The authors found no difference

Read more
  • What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?

Maintained virologic response to entecavir or lamivudine associates with short- and long-term transplant-free survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis, researchers report in the December issue of Clinical Gastroenterology and Hepatology. The benefits are maintained for up to 10 years, but patients are still at risk for

Read more